OMEGA 3 FATTY ACIDS SUPPLEMENTS IN WOMEN AT HIGH RISK FOR BREAST CANCER

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 基于细胞培养和啮齿动物研究，欧米茄3脂肪酸可以预防乳腺癌的生长和发展。 我们实验室的最新数据表明，只有某些乳腺癌可能对饮食中脂肪类型的差异有反应。 然而，为了研究omega 3脂肪酸对人类乳腺癌的影响，需要更多关于高风险和乳腺癌患者中特定剂量omega 3脂肪酸膳食补充剂相关的毒性，耐受性和乳腺组织摄取的信息。 因此，我们提出了一项为期6个月的剂量反应研究的omega 3脂肪酸的患者在高风险的发展乳腺癌，利用4个不同剂量的高浓度omega 3脂肪酸补充剂（Omacor）。 这项研究是对omega 3脂肪酸用于乳腺癌预防和/或治疗的更大，长期临床试验的重要第一步。 在0、3和6个月时通过细针抽吸获得的乳房脂肪样本将检查脂肪酸含量的变化，沿着每月血液样本以监测当前膳食脂肪酸摄入量。 将在0、3和6个月时采集血样，以确定对血脂、血小板功能、肝功能以及乳腺癌风险和/或ω 3脂肪酸的潜在生物标志物的影响。 通过每日录入日志和与研究人员定期沟通，监测患者的不良事件。 3天饮食记录和食物频率问卷将用于监测日常饮食。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Based on cell culture and rodent studies, omega 3 fatty acids prevent the growth and development of breast cancer. Recent data from our laboratory indicate the possibility that only certain breast cancers may respond to differences in the type of fat in the diet. In order to study the effects of omega 3 fatty acids on human breast cancer, however, additional information is needed regarding toxicity, tolerability and breast tissue uptake associated with specific doses of omega 3 fatty acid dietary supplements in high risk and breast cancer patients. Therefore, we propose a 6 month dose-response study of omega 3 fatty acids in patients at high risk of developing breast cancer, utilizing 4 different doses of a highly concentrated omega 3 fatty acid supplement (Omacor). This study is an essential first step towards larger, long term clinical trials of omega 3 fatty acids for breast cancer prevention and/or therapy. Breast fat samples obtained by fine needle aspiration at 0, 3 and 6 months will be checked for changes in fatty acid content, along with monthly blood samples to monitor current dietary fatty acid intake. Blood samples will be obtained at 0, 3 and 6 months to determine effects on lipid profile, platelet function, liver function, and potential biomarkers of breast cancer risk and/or omega 3 fatty acids. Patients will be monitored for adverse events via daily entries into logbooks and regular communication with study personnel. 3 day diet records and food frequency questionnaires will be used to monitor usual diets.